ReviewCancer2026
Targeting HIF-2α in renal cell carcinoma: Expanding upon belzutifan.
Review in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.Urologic oncology · 2026Article
- Von Hippel-Lindau Syndrome: An Updated Narrative Review for the First-Contact Clinician.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is a common subtype of kidney cancer driven by the inactivation of the von Hippel-Lindau (VHL) gene, leading to the accumulation of hypoxia-inducible factor (HIF)-2α and tumorigenesis.
methodsTargeting HIF-2α has emerged as a promising therapeutic strategy culminating in the development of a first-in-class inhibitor, belzutifan, invented by Peloton Therapeutics and marketed by Merck. This article presents the journey to belzutifan and subsequent developments.
resultsWe discuss the structure-based design leading to the first-in-human drug, PT2385, as well as subsequent modifications to improve pharmacokinetic properties leading to PT2977/belzutifan. Detailed analyses are presented of key HIF-2α structural features, the mechanism of drug action, and how this family of drugs performed in preclinical models. Belzutifan's impact on patients with VHL syndrome, sporadic advanced ccRCC and pheochromocytoma/paraganglioma is discussed, three areas where belzutifan has obtained Food and Drug Administration approval. Drug combination strategies, mechanisms of resistance, and emerging strategies to overcome them, including siRNA-based therapeutics, are presented. Alternative HIF-2α inhibitors are examined, including NKT2152 and AB521.
conclusionsBy expanding upon the foundation established by belzutifan, the field is poised for further therapeutic advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.